- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03573661
A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers (BCL)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary purpose of the study is to determine whether a device called the Breast Cancer Locator (BCL) accurately identifies the location of cancer in the breast. The Breast Cancer Locator is a plastic bra-like form that gives the surgeon information about the location of the cancer in the breast. The location information is derived from an MRI which is obtained with the patient lying flat on their back (just as they are on an operating room table). The BCL is then custom-made for the patient using 3D printing technology.
The surgeon can feel the cancer, and the surgeon will remove the cancer by feeling the edges of it as the surgeon would normally. Since the cancer can be felt, the surgeon does not need an image guidance system such as the BCL to locate the cancer in the breast. Other women may have breast cancers that cannot be felt, but are only identified by mammography or MRI. If the BCL proves to accurately localize breast cancer, it may be a useful guide for the surgeon for these other women.
Additionally, the investigators want to determine whether this technology can be successfully employed at multiple sites and what, if any, complications occur during surgery as a result of using this device. The BCL has been used in 19 patients at Dartmouth with no complications.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Burlington, Massachusetts, United States, 01805
- Lahey Hospital & Medical Center (Lahey Clinic)
-
-
New Hampshire
-
Keene, New Hampshire, United States, 03431
- Cheshire Medical Center
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth Hitchcock Medical Center
-
Nashua, New Hampshire, United States, 03060
- St. Joseph Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years.
- Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ.
- Patient desire to undergo breast surgery (lumpectomy or non-skin sparing mastectomy).
- Ability to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted.
- The cancer enhances on prone breast MRI imaging
- The cancer is visible on mammography.
Exclusion Criteria:
- Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes.
- Severe claustrophobia.
- Contraindication to use of gadolinium-based intravenous contrast, including life- threatening allergy or compromised renal function (creatinine > 2.0).
- History of median sternotomy.
- Pregnancy. Patient attestation that they are not pregnant will be acceptable.
- Patients receiving neoadjuvant chemotherapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Breast Cancer Locator (BCL)
The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position.
This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
|
This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of patients who had the localization wire placed within the cancer on the specimen mammogram
Time Frame: Within approximately 60 Days post-surgery (all measures are collected by the time of patient follow-up visit within approximately 60 days after surgery, and recorded by the surgeon and radiologist in Case Report Forms (CRF forms).
|
Yes/No answer from Radiologist.
Final measure will be % of cases rated Yes (wire deployed within the cancer on specimen mammogram).
|
Within approximately 60 Days post-surgery (all measures are collected by the time of patient follow-up visit within approximately 60 days after surgery, and recorded by the surgeon and radiologist in Case Report Forms (CRF forms).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Whether the study Radiologist can accurately define boundaries of the tumor from the supine MRI images
Time Frame: Within approximately 60 days following surgery
|
Yes/No answer from Radiologist.
Final measure will be % of cases rated Yes (tumor segregated accurately from supine MRI).
The data is recorded by the radiologist on the CRF form.
|
Within approximately 60 days following surgery
|
Time from supine MRI to delivery of the Breast Cancer Locator (BCL) device to the surgeon
Time Frame: Within approximately 60 days following surgery
|
Unit of measure is in days.
Final measure will be average days to delivery among all patients.
The data is recorded by the surgeon on the CRF form.
|
Within approximately 60 days following surgery
|
Whether the BCL allowed the surgeon to successfully mark in/on the breast skin surface the items he or she needs to see during the surgery, including tumor edges and locations where wires will be placed
Time Frame: Within approximately 60 days following surgery
|
Yes/No answer from Surgeon.
Final measure will be % of cases rated Yes (BCL enabled surgeon to successfully place all cues).
The data is recorded by the surgeon on the CRF form.
|
Within approximately 60 days following surgery
|
Lumpectomy specimen volumes
Time Frame: Within approximately 60 days following surgery
|
Unit of measure is in mL, calculated by water displacement.
Final measure will be average volume (mL) among all patients.
The data is recorded by the study sponsor, Cairn Surgical, on the CRF form.
|
Within approximately 60 days following surgery
|
Operative times (Average time per operation)
Time Frame: Within approximately 60 days following surgery
|
Unit of measure is in minutes.
Final measure will be average operative time (min.)
among all patients.
Data is collected by the surgeon from operative notes and placed in the CRF form.
|
Within approximately 60 days following surgery
|
The tumor margins, which the pathologist measures (as the distance from the tumor to the specimen edge)
Time Frame: Within approximately 60 days following surgery
|
Unit of measure is in cm.
Final measure will be average margin (in cm) among all patients.
Data is collected by the surgeon from the pathology report and reported in the CRF form.
|
Within approximately 60 days following surgery
|
Complications from surgery
Time Frame: Within approximately 60 days following surgery
|
Surgeon to list any complications - which could include infections or bruising.
Final measure will be % of patients with complications.
Data is collected from the surgeon either post-operatively, if there were operative complications; or at the post-operative follow-up appointment with the patient, if she reports any complications then.
It is also possible this data could be collected at any time between surgery and follow up appointment by the patient calling the surgeon's office to report it.
The surgeon records this data in the CRF form.
|
Within approximately 60 days following surgery
|
Surgeon satisfaction with the technical aspects of surgery guided by the Breast Cancer Locator
Time Frame: Within approximately 60 days following surgery
|
Yes/No answer.
Final measure will be % of surgeons who say Yes to satisfaction with the procedure.
Data is collected from the surgeon and reported in the CRF form.
|
Within approximately 60 days following surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Richard J Barth, Jr., MD, Dartmouth-Hitchcock Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D16196
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Palpable Breast Cancer
-
Kashani Social Security HospitalUnknownPalpable Breast MassIran, Islamic Republic of
-
Health BeaconsWithdrawnNon-palpable Breast LesionsUnited States
-
Agalimmune Ltd.CompletedSuperficial, Palpable, Unresectable/Metastatic Solid TumourUnited States, Israel, United Kingdom
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
Clinical Trials on Breast Cancer Locator (BCL)
-
Dartmouth-Hitchcock Medical CenterCompletedBreast CancerUnited States
-
CairnSurgical, Inc.SuspendedBreast Cancer FemaleUnited States, Canada, United Kingdom
-
Washington University School of MedicineNational Institute on Minority Health and Health Disparities (NIMHD)CompletedOncology | Breast Cancer Screening | Mammography | Preventative MedicineUnited States
-
First Affiliated Hospital, Sun Yat-Sen UniversityThe First Affiliated Hospital with Nanjing Medical University; Peking University... and other collaboratorsRecruiting
-
Samsung Medical CenterRecruitingBreast Cancer | Breast NeoplasmsKorea, Republic of
-
Centre Leon BerardThe Biostatistics and Therapy Evaluation Unit; BEC (Department of Clinical...CompletedBreast Cancer | Lung CancerFrance
-
AHS Cancer Control AlbertaRecruiting
-
Istanbul Aydın UniversityActive, not recruiting
-
Okan UniversityUnknownBreast Cancer | Breast Neoplasms | Surgery | Oncology
-
The Netherlands Cancer InstituteCompleted